Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
January 10, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter...
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
January 07, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical...
Biodesix Announces Third Quarter 2024 Results and Highlights
November 01, 2024 06:00 ET
|
Biodesix, Inc.
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and...
Biodesix to Participate in Three Investor Conferences in November
October 29, 2024 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive...
Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR
March 26, 2019 09:00 ET
|
Biodesix, Inc.
BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
November 12, 2018 09:00 ET
|
Biodesix, Inc.
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018 BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...
Biodesix Advances ORACLE Registry for Lung Nodule Cancer Test
October 30, 2018 08:27 ET
|
Biodesix, Inc.
Noninvasive Test to Rule Out Cancer Expected to Lower Patient Anxiety and Costs BOULDER, Colo., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Biodesix® today provided an update on the Observational Registry...
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
October 22, 2018 03:00 ET
|
Biodesix, Inc.
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix®...
Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules in New CHEST Data Publication
September 10, 2018 08:18 ET
|
Biodesix, Inc.
BOULDER, Colo., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Biodesix today announced newly published data showing the noninvasive BDX-XL2 test, currently in development, could reduce the number of...
Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
August 29, 2018 08:21 ET
|
Biodesix, Inc.
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) -- A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell...